Selexis CHO Cells in Suspension-1

Archives 2016

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades. 

NOVEMBER 15, 2016
6 min read

Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune Diseases

Selexis SA and OSE Immunotherapeutics Collaborate to Advance Development of Immunotherapies for Cancer and Autoimmune...

Read More
NOVEMBER 3, 2016
2 min read

Selexis and Xencor Enter Strategic Agreement, Strengthening Existing Relationship for Multi-Specific Antibody Cell Line Development

Geneva, Switzerland, 3 November 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
OCTOBER 25, 2016
2 min read

Selexis SA Inks Commercial Cell Line License Agreement with ImmuNext, Inc.  for Anti-CD40L Antibody Being Developed for Treatment of Chronic Autoimmune Disorders

Geneva, Switzerland, 25 October 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
OCTOBER 10, 2016
2 min read

Selexis SA Announces Participation at Two Upcoming Industry Conferences

Geneva, Switzerland, 10 OCTOBER 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
OCTOBER 6, 2016
3 min read

Selexis Chairman and CEO Dr. Igor Fisch Receives Prestigious Award for Excellence in Leadership from BioProcess International

Geneva, Switzerland, 6 October 2016 – BioProcess International (BPI) has named Selexis Chairman and Chief Executive...

Read More
SEPTEMBER 22, 2016
2 min read

Selexis SA and IAVI Expand Collaboration to Advance Multiple HIV Vaccine Candidates Toward Clinical Testing

Organizations to Jointly Develop High Performance Research Cell Banks to Expedite the Manufacturing of Engineered HIV...

Read More
SEPTEMBER 7, 2016
2 min read

Selexis SA Enters into Commercial Cell Line License Agreement with Pieris Pharmaceuticals for Immuno-Oncology Bispecific Drug Candidate

Geneva, Switzerland, 7 September 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
JULY 27, 2016
2 min read

ASLAN Pharmaceuticals Enters Service Agreement with Selexis SA for Development of a Proprietary Cell Line for Expression of ASLAN004

Geneva, Switzerland, and Singapore, 27 July 2016 – Selexis SA, a pioneering life sciences company and a global leader...

Read More
JULY 7, 2016
2 min read

Turgut Ilaclari A.S. and Selexis SA Sign Service and Commercial Agreements to Progress Development of Biosimilar Products

Turgut Ilaclari A.S. and Selexis SA Sign Service and Commercial Agreements to Progress Development of Biosimilar...

Read More
JUNE 26, 2016
2 min read

Symphogen A/S Advances Sym015 into Clinical Development Using Selexis SGE (Selexis Genetic Elements)

Geneva, Switzerland, 29 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
JUNE 21, 2016
1 min read

Progenics Pharmaceuticals, Inc. Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform

Geneva, Switzerland, 21 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
JUNE 2, 2016
1 min read

Liomont Signs Commercial License Agreement with Selexis SA for Use of Proprietary Cell Line and SUREtechnology Platform

Geneva, Switzerland, 2 June 2016 – Selexis SA, a pioneering life sciences company and a global leader in mammalian...

Read More
APRIL 17, 2016
1 min read

Selexis SA Launches SURE CHO-Mplus Libraries

Technology Addresses Secretion Bottlenecks in Recombinant Protein Expression

Geneva, Switzerland (PRWEB) April 17, 2013...

Read More
MARCH 31, 2016
1 min read

Selexis SA Announces Spring 2016 Conference Schedule

Selexis leadership planning for active lineup of speaking engagements, partnering and exhibit activities, and...

Read More